Anhui Anke Biotechnology (300009.SZ) intends to participate as a cornerstone investor in the listing of Weisheng Pharmaceutical's H shares IPO.

Anhui Anke Biotechnology (300009.SZ) announced that the board of directors has agreed for the company to use its own funds of no more than 31 million USD (including brokerage commissions and related fees) through its wholly-owned subsidiary Anhui Anke Biotechnology (Hong Kong) Limited (referred to as "Anhui Anke Biotechnology (Hong Kong)"), to participate as a cornerstone investor in the initial public offering of shares to be issued by WeShine Pharmaceuticals on the Hong Kong Stock Exchange, and to sign a "Cornerstone Investment Agreement", with the specific shareholding proportion to be determined based on the issuance market value. According to the announcement, WeShine Pharmaceuticals is a late-stage R&D biopharmaceutical company with products nearing commercialization, focusing on providing specific treatment solutions for endocrine disorders in China. Its core product, Long-Acting Growth Hormone (LGH), is a once-weekly long-acting growth hormone replacement therapy. With its innovative molecular design, LGH is the only long-acting growth hormone that can release unmodified human growth hormone continuously between weekly doses. In global Phase III positive drug control and parallel group comparison trials, LGH has demonstrated superior efficacy to short-acting (daily injection) human growth hormone. Completed pivotal Phase III trials in China continue to support the superior efficacy and comparable safety of LGH compared to short-acting (daily injection) human growth hormone. Navepinatide, one of the key candidate drugs, is a long-acting prodrug of C-type natriuretic peptide used to treat achondroplasia (a short-limb dwarfism that can lead to severe skeletal complications and comorbidities). Another key candidate drug, Paroketeliparteletropapide, is a once-daily parathyroid hormone replacement therapy for the treatment of chronic hypoparathyroidism (a calcium-phosphate metabolism disorder syndrome caused by decreased secretion or functional defects of parathyroid hormone). It is reported that this external investment is beneficial for optimizing the company's capital operation efficiency and expanding its influence in the capital market. In addition, by promoting close long-term cooperation with WeShine Pharmaceuticals through this investment, the company aims to drive deep strategic cooperation in their respective areas of expertise, facilitating resource integration and complementarity to fully leverage industrial synergies.